Qube Research & Technologies (QRT)
JAZZ icon

Qube Research & Technologies (QRT)’s Jazz Pharmaceuticals JAZZ Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$70.1M Buy
290,725
+28,172
+11% +$6.17M 0.07% 390
2026
Q1 		$49.6M Sell
262,553
-237,933
-48% -$41.6M 0.06% 429
2025
Q4 		$85.1M Buy
500,486
+444,242
+790% +$68.1M 0.09% 300
2025
Q3 		$7.41M Sell
56,244
-66,978
-54% -$8.03M 0.01% 1501
2025
Q2 		$13.1M Sell
123,222
-204,247
-62% -$22.2M 0.01% 1134
2025
Q1 		$40.7M Buy
327,469
+272,079
+491% +$35.5M 0.05% 481
2024
Q4 		$6.82M Sell
55,390
-43,961
-44% -$5.18M 0.01% 1323
2024
Q3 		$11.1M Buy
99,351
+93,651
+1,643% +$10.3M 0.02% 980
2024
Q2 		$608K Sell
5,700
-72,801
-93% -$8M ﹤0.01% 2082
2024
Q1 		$9.45M Sell
78,501
-289,234
-79% -$35.4M 0.02% 882
2023
Q4 		$45.2M Buy
367,735
+76,157
+26% +$9.5M 0.09% 285
2023
Q3 		$37.7M Sell
291,578
-97,299
-25% -$13M 0.1% 252
2023
Q2 		$48.2M Buy
388,877
+286,600
+280% +$38.6M 0.18% 160
2023
Q1 		$15M Buy
102,277
+29,958
+41% +$4.43M 0.06% 334
2022
Q4 		$11.5M Sell
72,319
-24,005
-25% -$3.52M 0.06% 436
2022
Q3 		$12.8M Buy
+96,324
New +$14.6M 0.08% 350
2022
Q1 		– Sell
-29,072
Closed -$3.7M – 2736
2021
Q4 		$3.7M Buy
+29,072
New +$3.82M 0.03% 641
2021
Q3 		– Sell
-4,978
Closed -$884K – 2499
2021
Q2 		$884K Sell
4,978
-29,821
-86% -$5.17M 0.01% 996
2021
Q1 		$5.72M Buy
+34,799
New +$5.73M 0.09% 288
2020
Q3 		– Sell
-11,071
Closed -$1.22M – 1898
2020
Q2 		$1.22M Sell
11,071
-337
-3% -$37.3K 0.02% 799
2020
Q1 		$1.14M Sell
11,408
-10,032
-47% -$1.3M 0.05% 353
2019
Q4 		$3.2M Buy
+21,440
New +$2.92M 0.1% 234
2018
Q4 		– Sell
-100
Closed -$17K – 591
2018
Q3 		$17K Buy
+100
New +$17.2K ﹤0.01% 963

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Qube Research & Technologies (QRT)'s JAZZ Position: Q2 2026 in Review

Qube Research & Technologies (QRT) increased its Jazz Pharmaceuticals (JAZZ) stake by 11% in Q2 2026, buying an estimated $6.17M and bringing the position to 290,725 shares worth $70.1M. The position accounts for 0.07% of the portfolio, ranked #390.

Qube Research & Technologies (QRT) first reported a position in JAZZ in Q3 2018 and has held it in 23 quarters since. The position peaked at $85.1M in Q4 2025. 645 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

  • Qube Research & Technologies (QRT) held 290,725 shares of Jazz Pharmaceuticals worth $70.1M as of Q2 2026.
  • Qube Research & Technologies (QRT) bought 28,172 Jazz Pharmaceuticals shares in Q2 2026, an estimated $6.17M.
  • Jazz Pharmaceuticals made up 0.07% of Qube Research & Technologies (QRT)'s portfolio in Q2 2026, its #390 holding.
  • Qube Research & Technologies (QRT) first reported a position in Jazz Pharmaceuticals in Q3 2018 and has held it in 23 quarters since.
  • Qube Research & Technologies (QRT)'s Jazz Pharmaceuticals position peaked at $85.1M in Q4 2025.
  • 645 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2026, filed 14 Aug 2026.